T-curx

Developer of immune-based cancer treatments with T-cells

placeWurzburg, Bavaria, Germany calendar_todayFounded 2016 language t-curx.com

Registered entities

Social engagement

Social engagement: 2K social following, 5 posts in the last 12 months — below the industry typical range.

Investor mix

5 investors on record; lead investors include BioMedPartners.

Investor typeCountShare
Venture capital240%
Other / undisclosed360%

Recent activity

11 Jun 2026
Milestone
regulatory
28 May 2026
Event
7th International Cell and Gene Therapy China Summit
13 Feb 2026
Partnership
Britiel Cancer Institute (BCI)
Coming soon